Novo Nordisk's stock price rose 7% as sales of its weight loss drug Wegovy were positive in the first week of launch
Novo Nordisk (NVO.US) saw its stock price rise over 7% on Friday, as its new GLP-1 drug Wegovy for treating obesity achieved positive results in its initial launch in the United States.
Analysts reported that Novo Nordisk's new weight loss drug had approximately 4,290 prescriptions written in its first week on the market, most of which were for the initial dosage; in contrast, Eli Lilly's (LLY.US) weight loss drug Zepbound had about 1,900 prescriptions in its first week. The drug was approved at the end of December last year and officially launched on January 5
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments